Live
FierceBiotechShionogi pays Apnimed $100M for joint venture to awaken sleep disorder dreamFierceBiotechOcugen eye disease gene therapy hits ph. 2 targets but underwhelms investorsEndpoints NewsOcugen heads to Phase 3 with gene therapy for geographic atrophyEndpoints NewsLessons from the last health tech revolutionEndpoints NewsFDA warns ImmunityBio over misleading podcast with Patrick Soon-ShiongThermo FisherThermo Fisher Scientific Completes Acquisition of Clario Holdings, Inc. - pharmiweb.comAgilentDirector Of Agilent Technologies Purchased $340K In Stock - BenzingaThermo FisherThermo Fisher Scientific (TMO) Completes Acquisition of Clario H - GuruFocusAgilentAgilent Technologies (A) to Acquire Biocare Medical for $950M - Insider MonkeyThermo FisherThermo Fisher Scientific (TMO) Partners With AIM ImmunoTech on Phase 3 Cancer Trial - Insider MonkeyEndpoints NewsKaryopharm’s mixed myelofibrosis data; Rezolute to seek FDA approval despite trial failureEndpoints NewsQ&A: Controversial embryo editing entrepreneur Cathy Tie on her new startup
Endpoints News Jan 8, 2026

FDA rejects Vanda’s jet lag drug following yearslong dispute

FDA rejects Vanda’s jet lag drug following yearslong dispute

Original
Body unavailable. Use the original source.

Directory

59 All